Sutro Biopharma (STRO) Equity Income (2020 - 2024)

Sutro Biopharma has disclosed Equity Income across 5 years of filings, most recently posting $4.8 million for Q2 2024.

• Equity Income for Q2 2024 came in at $4.8 million, down 42.22% year-over-year; the trailing twelve-month figure through Mar 2025 was $4.8 million (down 76.65% YoY), and the FY2023 annual result was $9.9 million, down 18.24% from the prior year.
• Equity Income came in at $4.8 million for Q2 2024 at Sutro Biopharma, up from $3.7 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $48.9 million in Q2 2020 to a low of -$37.1 million in Q4 2020.
• The 5-year median for Equity Income is $3.7 million (2024), against an average of $4.0 million.
• Across the five-year window, Equity Income surged 558.88% in 2022 and sank 1341.92% in 2023, its largest moves.
• Sutro Biopharma's Equity Income stood at -$37.1 million in 2020, then jumped by 93.07% to -$2.6 million in 2021, then soared by 558.88% to $11.8 million in 2022, then plunged by 33.14% to $7.9 million in 2023, then slumped by 39.09% to $4.8 million in 2024.
• The last three Equity Income figures came in at $4.8 million (Q2 2024), $3.7 million (Q1 2024), and $7.9 million (Q4 2023), per Business Quant data.